Febuxostat (Uloric) Can Be Continued on the Day of Surgery
Febuxostat (Uloric) does not need to be discontinued before anesthesia or surgery and can be safely continued throughout the perioperative period. Unlike medications that require specific perioperative management (such as anticoagulants, ACE inhibitors, or certain diabetes medications), febuxostat—a xanthine oxidase inhibitor used for chronic gout management—has no documented anesthetic interactions or perioperative risks that would necessitate discontinuation.
Rationale for Continuation
No Perioperative Contraindications
The FDA label for Uloric 1 provides comprehensive prescribing information but contains no warnings or precautions regarding perioperative use or anesthesia interactions. The drug can be taken without regard to food or antacid use, and dosing remains straightforward at 40-80 mg once daily 1.
Lack of Withdrawal Concerns
Unlike medications that carry specific perioperative risks:
- Beta-blockers and clonidine must be continued to avoid rebound hypertension 2
- ACE inhibitors/ARBs may be held to prevent intraoperative hypotension 2
- Anticoagulants require careful timing around procedures 3, 4
- Metformin and SGLT2 inhibitors need specific perioperative management 5
Febuxostat has no such documented perioperative concerns and does not appear in any major perioperative medication management guidelines 2, 6, 5, 3, 7.
Gout Flare Prevention
Continuing febuxostat through the perioperative period may actually be beneficial to prevent gout flares triggered by surgical stress. The FDA label explicitly states that if a gout flare occurs during treatment, "ULORIC need not be discontinued" 1. Discontinuing urate-lowering therapy can lead to gout relapses in 36-81% of patients within 1-4.5 years 8, though the immediate perioperative risk is less well-defined.
Practical Management Algorithm
For all patients on febuxostat undergoing surgery:
- Continue febuxostat at the usual dose (40 mg or 80 mg once daily) through the morning of surgery
- Resume immediately postoperatively once oral intake is tolerated
- No dose adjustment needed for renal impairment (mild-moderate) or hepatic impairment 1
- Monitor for gout flares in the postoperative period, as surgical stress itself can trigger flares
Important Caveats
Cardiovascular Considerations
The FDA has issued a black box warning for febuxostat regarding cardiovascular events 1. While this relates to chronic use rather than perioperative management specifically, patients with established cardiovascular disease taking febuxostat warrant heightened monitoring for MI and stroke symptoms perioperatively 1. This does not mean the drug should be stopped for surgery—rather, maintain usual cardiovascular vigilance.
Drug Interactions
Febuxostat is contraindicated with azathioprine, mercaptopurine, and theophylline 1. Verify the patient is not on these medications, but this is a chronic concern unrelated to surgery timing.
NPO Status
If the patient will be NPO (nothing by mouth) for an extended period postoperatively, febuxostat can be held temporarily and resumed when oral intake restarts. The drug's mechanism (xanthine oxidase inhibition for chronic urate lowering) does not require continuous daily dosing for acute perioperative safety.
Bottom Line
There is no evidence-based reason to discontinue febuxostat before anesthesia or surgery. The absence of this medication from comprehensive perioperative medication management guidelines 2, 6, 5 and the lack of perioperative warnings in the FDA label 1 support continuation through the surgical period. This approach maintains therapeutic urate control and avoids potential gout flares from unnecessary medication interruption.